Tam CS - Search Results

1

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Byrd JC, et al. Among authors: tam cs. N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. N Engl J Med. 2014. PMID: 24881631 Free PMC article. Clinical Trial.

2

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. Tam CS, et al. Leuk Lymphoma. 2007 Oct;48(10):1931-9. doi: 10.1080/10428190701573257. Leuk Lymphoma. 2007. PMID: 17917961

3

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Tam CS, et al. Blood. 2008 Aug 15;112(4):975-80. doi: 10.1182/blood-2008-02-140582. Epub 2008 Apr 14. Blood. 2008. PMID: 18411418 Free PMC article. Clinical Trial.

4

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.

Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J, Cortes J. Tam CS, et al. Blood. 2008 Aug 1;112(3):516-8. doi: 10.1182/blood-2008-02-141580. Epub 2008 May 20. Blood. 2008. PMID: 18492956 Free PMC article. Clinical Trial.

5

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Lin KI, et al. Among authors: tam cs. Blood. 2009 Apr 2;113(14):3168-71. doi: 10.1182/blood-2008-10-184853. Epub 2008 Dec 2. Blood. 2009. PMID: 19050308 Free PMC article. Clinical Trial.

6

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia.

Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Tsimberidou AM, et al. Cancer. 2009 Jan 15;115(2):373-80. doi: 10.1002/cncr.23993. Cancer. 2009. PMID: 19117034 Free PMC article.

7

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. Tam CS, et al. Blood. 2009 Jul 30;114(5):957-64. doi: 10.1182/blood-2009-03-210591. Epub 2009 May 4. Blood. 2009. PMID: 19414856 Free PMC article.

8

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.

Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Jabbour E, et al. Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30. Blood. 2009. PMID: 19567878 Free PMC article.

9

p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Schlette EJ, Admirand J, Wierda W, Abruzzo L, Lin KI, O'Brien S, Lerner S, Keating MJ, Tam C. Schlette EJ, et al. Leuk Lymphoma. 2009 Oct;50(10):1597-605. doi: 10.1080/10428190903165241. Leuk Lymphoma. 2009. PMID: 19863337 Free PMC article. Clinical Trial.

10

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.

Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Strati P, et al. Cancer. 2013 Nov 1;119(21):3805-11. doi: 10.1002/cncr.28318. Epub 2013 Aug 13. Cancer. 2013. PMID: 23943357 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page